Radiopharm Theranostics Ltd Logo

Radiopharm Theranostics Ltd

Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.

RADX | US

Overview

Corporate Details

ISIN(s):
US75041J1016
LEI:
Country:
United States of America
Address:
LEVEL 3, 62 LYGON STREET, 3053 CARLTON VIC
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Radiopharm Theranostics is a clinical-stage biotechnology company developing a portfolio of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company is advancing a diverse pipeline based on proprietary platforms—including antibodies, nanobodies, peptides, and small molecules—to address significant unmet needs in oncology. Its strategy focuses on pioneering novel oncology targets, distinguishing itself from therapies aimed at more established pathways. Key differentiators include strategic collaborations, such as a joint venture with MD Anderson Cancer Center, and a focus on operational excellence and reliable isotope supply chains.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Radiopharm Theranostics Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Radiopharm Theranostics Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Radiopharm Theranostics Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX
Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM
PTC THERAPEUTICS, INC. Logo
Develops and commercializes pioneering medicines for patients with rare diseases.
United States of America
PTCT
Pulmatrix, Inc. Logo
Develops inhaled therapies for respiratory and CNS disorders using its iSPERSE™ technology.
United States of America
PULM
PUMA BIOTECHNOLOGY, INC. Logo
Develops and commercializes innovative cancer therapeutics, with an approved drug and a clinical pipeline.
United States of America
PBYI
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland
PUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.